Lightning Flash features Penumbra's novel Lightning Intelligent Aspiration technology, now with dual clot detection algorithms. Together with innovative catheter engineering, Lightning Flash is designed to quickly remove large blood clots in the body, including venous thrombus and pulmonary emboli (PE).
Penumbra's Lightning Flash gives physicians a highly torqueable, larger catheter that is designed to remove a large clot burden in the pulmonary arteries or deep venous system more efficiently while maintaining an excellent safety profile because of Lightning's computer-aided algorithms,' said
Lightning Flash, powered by the Penumbra ENGINE, uses both pressure and flow-based algorithms to detect blood clot and blood flow. The Lightning Flash catheter is made with MaxID hypotube technology, allowing an inner diameter similar to large-bore catheters while maintaining a lower profile and a soft, atraumatic tip designed to help navigate the complex and delicate anatomy of the body. When used together, the device is intended to help remove blood clots quickly while minimizing potential blood loss.
Lightning Flash will fundamentally change how blood clots are removed from the body,' said
Lightning Flash is part of Penumbra's Indigo System with Lightning portfolio. Lightning products are the only computer-aided mechanical thrombectomy systems currently available in the
Penumbra's commitment to innovation and clinical excellence enables us to pioneer interventional therapies that have a significant impact on patients,' said Sandra Lesenfants, president of interventional at
About Penumbra
Important Safety Information
Additional information about Penumbra's products can be located on Penumbra's website at http://www.penumbrainc.com/healthcare-professionals. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use. Risk information can be found here.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operations and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the
Contact:
Tel: 510-995-9791
Email: jheth@penumbrainc.com
(C) 2023 Electronic News Publishing, source